Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

INmune Bio Inc. - Common stock (NQ:INMB)

1.540 -0.020 (-1.28%)
Streaming Delayed Price Updated: 10:49 AM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about INmune Bio Inc. - Common stock

< Previous 1 2 3 4 Next >
News headline image
Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio’s CORDStrom™ Platform
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Reports New Phase 2 Grey Matter Imaging Data at CTAD Conference Reinforcing XPro1595’s Evidence Base in High-Inflammation Alzheimer's Patients
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Announces Two Presentations at the Upcoming 18th Annual CTAD Conference
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on Thursday, October 30, 2025
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio to Participate in Dermatologic Rare Disease Panel at the Maxim Growth Summit 2025
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Announces Submission of Phase 2 MINDFuL Trial Results in Alzheimer’s Disease to npj Dementia, a Nature Portfolio Journal
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Announces Successful Completion of First Commercial Pilot-Scale Manufacturing Run of CORDStrom™ at CGT Catapult
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio’s CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7th
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio to Publish Video Detailing MINDFuL Trial Findings of XPro™ Presented at the Alzheimer’s Association International Conference
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio to Present Phase 2 MINDFuL Trial Findings of XPro™ at the Alzheimer’s Association International Conference
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio, Inc. Announces Closing of Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro™ in Early Alzheimer’s Disease
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio, Inc. Announces Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Inc. to Announce Top Line Results from MINDFuL Phase 2 Trial in Early Alzheimer’s on Monday, June 30th
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
XPro™ Reduces Amyloid and Enhances Behavior Post Traumatic Brain Injury in an Animal Model of Alzheimer’s Disease: Supported by Department of Defense
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Inc. Announces Attendance at the 2025 RBC Capital Markets Global Healthcare Conference
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on Thursday, May 8th
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Receives Favorable Patentability Opinion for CORDStrom™ Platform Technology
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom™ Manufacturing for Commercial Readiness
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL Phase II Study
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Inc. to Report Fourth Quarter 2024 Financial Results and Provide Corporate Update on March 27, 2025
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Inc. Expands INKmune Trial in Prostate Cancer to Veterans
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Inc. Completes Repayment of Silicon Valley Bank Debt
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer’s Trial with Vivo, a Novel genAI Clinical Trial Control Tower
From OmniScience
Via Business Wire
News headline image
OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer’s Trial with Vivo, a Novel genAI Clinical Trial Control Tower
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB
From INmune Bio, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.